A Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Cetuximab and Radiation Therapy in Advanced Head and Neck MalignanciesBrandon M. Barney1*, Val Lowe2, Scott H. Okuno3, Bradley J. Kemp2, Mark S. Jacobson BA2, Katharine A. Price3, Jean E. Lewis4, Jan L. Kasperbauer5, Debra H. Brinkmann1, Robert L. Foote1, Yolanda I. Garces1, Wenting Wu6 and Jann N. Sarkaria1
- *Corresponding Author:
- Dr. Brandon Barney
Department of Radiation Oncology
Mayo Clinic, 200 First Street SW
Rochester, MN 55905, USA
E-mail: [email protected]
Received date: December 17, 2011; Accepted date: February 02, 2012; Published date: February 05, 2012
Citation: Barney BM, Lowe V, Okuno SH, Kemp BJ, Mark S. Jacobson BA, et al. (2012) A Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Cetuximab and Radiation Therapy in Advanced Head and Neck Malignancies. J Nucl Med Radiat Ther 3:120. doi:10.4172/2155-9619.1000120
Copyright: © 2012 Barney BM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: We prospectively compared FLT-PET and FDG-PET in evaluating response to cetuximab and chemoradiotherapy for HNSCC.
Methods: Six patients with HNSCC received cetuximab followed by chemoradiotherapy. Patients had FLTand FDG-PET scans at baseline, after cetuximab, and 2 weeks into chemoradiotherapy. Changes in SUVmax on successive scans were compared to baseline. Results: After induction therapy, changes in SUVmax ranged from -2 to 32% for FLT-PET and -24 to 0% for FDGPET. After two weeks of chemoradiotherapy, changes in SUVmax ranged from -71 to 9% for FLT-PET and -80 to -7% for FDG-PET. One patient experienced consecutive increases in FLT uptake not detected by FDG-PET. No patient recurred at a median 14.6 months.
Conclusions: Functional imaging early during definitive therapy for HNSCC is feasible. Similar changes in FLT and FDG uptake are detected during chemoradiotherapy; however, distinct differences were seen after induction cetuximab therapy. Further follow-up will facilitate correlation of radiotracer uptake with clinical outcome.